Literature DB >> 8528132

2,3-didehydro-2,4-dideoxy-4-guanidino-N-acetyl-D-neuraminic acid (4-guanidino-Neu5Ac2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus.

G J Hart1, R C Bethell.   

Abstract

The effect of 2,3-didehydro-2,4-dideoxy-4-guanidino-N-acetyl-D-neuraminic acid (4-guanidino-Neu5Ac2en) on the sialidases from influenza virus reassortant X31 (which contains the sialidase from A/Aichi/2/68) and influenza virus B/Beijing/1/87 has been investigated. We find that 4-guanidino-Neu5Ac2en is a slow-binding inhibitor of both influenza A and influenza B virus sialidase, and that association and dissociation rate constants are almost identical for both enzymes. Furthermore, values for these rate constants are independent of whether purified enzyme or detergent-treated virus is used in the assays.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8528132

Source DB:  PubMed          Journal:  Biochem Mol Biol Int        ISSN: 1039-9712


  12 in total

1.  Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.

Authors:  J L McKimm-Breschkin; T J Blick; A Sahasrabudhe; T Tiong; D Marshall; G J Hart; R C Bethell; C R Penn
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

2.  Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en.

Authors:  L V Gubareva; R Bethell; G J Hart; K G Murti; C R Penn; R G Webster
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

Review 3.  Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

Authors:  Jennifer L McKimm-Breschkin
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

4.  Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers.

Authors:  L M Cass; J Brown; M Pickford; S Fayinka; S P Newman; C J Johansson; A Bye
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

5.  Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.

Authors:  Michael Z Wang; Chun Y Tai; Dirk B Mendel
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Novel alpha- and beta-amino acid inhibitors of influenza virus neuraminidase.

Authors:  W M Kati; D Montgomery; C Maring; V S Stoll; V Giranda; X Chen; W G Laver; W Kohlbrenner; D W Norbeck
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

7.  Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen.

Authors:  Simon J F Macdonald; Keith G Watson; Rachel Cameron; David K Chalmers; Derek A Demaine; Rob J Fenton; David Gower; J Nicole Hamblin; Stephanie Hamilton; Graham J Hart; Graham G A Inglis; Betty Jin; Haydn T Jones; Darryl B McConnell; Andy M Mason; Van Nguyen; Ian J Owens; Nigel Parry; Phillip A Reece; Stephen E Shanahan; Donna Smith; Wen-Yang Wu; Simon P Tucker
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

8.  Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.

Authors:  Aaron J Oakley; Susan Barrett; Thomas S Peat; Janet Newman; Victor A Streltsov; Lynne Waddington; Takehiko Saito; Masato Tashiro; Jennifer L McKimm-Breschkin
Journal:  J Med Chem       Date:  2010-09-09       Impact factor: 7.446

Review 9.  New approaches to influenza chemotherapy. Neuraminidase inhibitors.

Authors:  D P Calfee; F G Hayden
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 10.  Preclinical development of low toxicity drugs: focus on zanamivir, an anti-influenza drug.

Authors:  G D Dines; R Bethell; M Daniel
Journal:  Drug Saf       Date:  1998-09       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.